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Abstract. 
 
To better understand proteasomal degrada-
tion of nuclear proteins and viral antigens we studied 
mutated forms of inﬂuenza virus nucleoprotein (NP) 
that misfold and are rapidly degraded by proteasomes. 
In the presence of proteasome inhibitors, mutated NP 
(dNP) accumulates in highly insoluble ubiquitinated 
and nonubiquitinated species in nuclear substructures 
known as promyelocytic leukemia oncogenic domains 
(PODs) and the microtubule organizing center 
(MTOC). Immunoﬂuorescence revealed that dNP re-
cruits proteasomes and a selective assortment of molec-
ular chaperones to both locales, and that a similar 
(though less dramatic) effect is induced by proteasome 
inhibitors in the absence of dNP expression. Biochemi-
cal evidence is consistent with the idea that dNP is de-
livered to PODs/MTOC in the absence of proteasome 
inhibitors. Restoring proteasome activity while block-
ing protein synthesis results in disappearance of dNP 
from PODs and the MTOC and the generation of a ma-
jor histocompatibility complex class I–bound peptide 
derived from dNP but not NP. These ﬁndings demon-
strate that PODs and the MTOC serve as sites of pro-
teasomal degradation of misfolded dNP and probably 
cellular proteins as well, and imply that antigenic pep-
tides are generated at one or both of these sites.
Key words: antigen presentation • molecular
chaperone • nuclear proteins proteolysis • ubiquitin/
immunology • proteasome
 
P
 
ROTEASOMES
 
 are complex multisubunit proteases
abundant in the nucleus and cytosol that function in
all eukaryotic cells to degrade damaged or un-
wanted proteins. The major means of tagging proteins for
proteasomal destruction is covalent modification by multi-
ple chains of ubiquitin (Ub)
 
1
 
 (Ciechanover, 1998). Incuba-
tion of cells with proteasome inhibitors results in the ac-
cumulation of polyubiquitinated proteins, and in most
circumstances, cell death (Bogyo et al., 1997; Lee and
Goldberg, 1998).
Proteasomes participate in the generation of many of
the peptides that are displayed on the cell surface in a
complex with class I molecules of the major histocompati-
bility complex for surveillance by the immune system
(York and Rock, 1996). Peptides are generated indiscrimi-
nately from host gene products and gene products of vi-
ruses and other intracellular pathogens (Pamer and Cress-
well, 1998). Discrimination between self and nonself
peptides is performed at the level of the antigen receptor
expressed by CD8
 
1
 
 T lymphocytes. There is sufficient
plasticity in the system to enable T cell recognition of
some self antigens, which accounts for the generation of
most defined T cell responses to tumors.
Although there has been rapid progress in understand-
ing the function of the proteasome-Ub system in cellular
metabolism, and more specifically, its role in generating
antigenic peptides, many important questions remain, in-
cluding the involvement of molecular chaperones in the
process, the intracellular sites of ubiquitination and pro-
teasomal degradation, and the nature of substrates that
provide antigenic peptides. In the present communication
we describe findings with a metabolically unstable form of
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1. 
 
Abbreviations used in this paper:
 
 APL, acute PML; dNP, misfolded nu-
cleoprotein; GFP, green fluorescent protein; LC, lactacystin; LCSM, laser
confocal scanning microscope; MTOC, microtubule organizing center;
NP, influenza virus nucleoprotein; NP
 
pep
 
, NP with SIINFEKL appended
to the COOH terminus; OVA, ovalbumin; PBC, primary biliary cirrhosis;
PML, promyelocytic leukemia; POD, PML oncogenic domain; RAR, ret-
inoic acid receptor; rVV, recombinant vaccinia virus; Ub, ubiquitin; zLLL,
cbz-LeuLeuLeucinal. 
The Journal of Cell Biology, Volume 146, 1999 114
 
influenza virus nucleoprotein (NP) that provide some ini-
tial answers to these questions.
 
Materials and Methods
 
Cells
 
143B human osteosarcoma cells lacking thymidine kinase and HeLa cells
were obtained from the American Type Culture Collection and main-
tained in DMEM supplemented with 7.5% (vol/vol) fetal bovine serum in
an air/CO
 
2
 
 (91%/9%) atmosphere at 37
 
8
 
C. L929 cells expressing K
 
b
 
 from
a transfected gene were maintained similarly.
 
Viruses
 
Recombinant vaccinia viruses (rVVs) were constructed by standard meth-
odology (Chakrabarti et al., 1985) using a modified form of pSC11 with
multiple cloning sites to express inserted genes under the control of the
p7.5 promoter active early and late in VV replication. dNPpep was con-
structed by inserting an oligonucleotide encoding KEKEKNKLKR-
KKLENKDKKDEERNKIREE at position 333 in NP
 
pep
 
. Green fluores-
cent protein (GFP) constructs were created by fusing NP
 
pep
 
 or dNP
 
pep
 
encoding constructs with a cDNA encoding EGFP (Clontech), a red-
shifted version of GFP modified by two substitutions (Phe
 
64
 
®
 
Leu,
Ser
 
65
 
®
 
Thr), and 190 synonymous coding alterations to match human
codon usage. For cloning convenience, sequences encoding the spacer
peptide ARDPPVAT were inserted between the COOH terminus of the
NP
 
pep 
 
constructs and initiating Met of GFP. Most VV infections were per-
formed with media containing cytosine arabinoside at 40 
 
m
 
g/ml to limit ex-
pression to viral gene products expressed under the control of early pro-
moters. This reduces the morphological alterations in cells induced by VV
and also controls for the blockade in late VV gene expression induced by
proteasome inhibitors (Antón et al., 1998).
 
Antibodies
 
Antipeptide antisera were prepared by immunizing rabbits with synthetic
peptides conjugated to KLH. Peptides corresponded to PR8 NP se-
quences 2-12 
 
1
 
Cys and Cys
 
1
 
488-498; the extraneous Cys being used for
conjugation and coupling to beads. The NH
 
2
 
-terminal–specific serum was
affinity purified against the synthetic peptide disulfide coupled to Sul-
foLink
 
®
 
 beads (Pierce Chemical Co.) and absorbed multiple times against
uninfected fixed and permeabilized cells to remove antibodies specific for
cellular proteins. The COOH-terminal antiserum could be used without
further purification. Monoclonal antibodies specific for the proteasome
(clones MCP20 and MCP21) were generously provided by K.B. Hendil
(University of Copenhagen, Copenhagen, Denmark). Human sera from
primary biliary cirrhosis (PBC) patients containing anti–promyelocytic
leukemia (PML) oncogenic domain (POD) antibodies were generously
provided by D.B. Bloch (Harvard Medical School, Charlestown, MA) and
J. Liang (NIDDK, Bethesda, MD). The colocalization of human antibody
staining of PODs in TK
 
2
 
 cells with the anti-PML mAb was confirmed.
The commercial sources of the following antibodies are as listed: poly Ub
mouse mAb, clone FK2, Nippon Bio-Test Laboratories; PML mouse mAb,
clone PG-M3, Santa Cruz Biotechnologies; 
 
g
 
-tubulin mouse mAb, clone
gtu-88, Sigma Chemical Co.; HSP27 mouse mAb, clone G3.1, HSP40 rab-
bit Ab (SPA-400), HSP47 mouse mAb, clone M16.10A1, HSP56 mouse
mAb, clone KN382/EC1, HSP60 mouse mAb, clone LK-1, HSC70 rat
mAb, clone 1B5, HSP70 mouse mAb, clone C92F3A-5, HSP90, rat mAb,
clone 16F1, and HSP110 rabbit Ab (SPA-1101), all from StressGen Bio-
technologies.
 
Immunofluorescence
 
Cells were grown overnight on acid-cleaned, 0.17-mm-thick, 12-mm-diam-
eter glass coverslips placed in 24-well plates, infected with virus, and incu-
bated as indicated in the text and figure legends. At the appropriate time,
cells were fixed by incubation with 3% (wt/vol) paraformaldehyde in PBS
for 20 min and permeabilized by 2 min of treatment with 1% (vol/vol) NP-
40 in PBS. After quenching of formaldehyde with 200 mM glycine/PBS,
cells were incubated with a mixture of primary antibodies diluted in PBS
supplemented with 5% (vol/vol) donkey serum, usually overnight, at 4
 
8
 
C,
washed, and incubated for 2–8 h in the same diluent containing secondary
donkey antibodies conjugated to DTAF, Texas red, or Cy5, specific for
 
mouse, human, rabbit, or rat Ig (Jackson ImmunoResearch). Coverslips
were mounted on glass slides with Fluoromount-G (Southern Biotechnol-
ogy) containing 15-
 
m
 
m-diameter beads to prevent cell compression, and
images collected with a Bio-Rad MRC1024 laser scanning confocal Zeiss
Axioplan microscope, using a 63
 
3
 
 planapochromat oil immersion objec-
tive. Controls established the specificity of fluorochrome-conjugated anti-
bodies for their respective Igs, and that signals in green, red, and far red
channels were derived from the respective fluor. Digital images were as-
sembled using Adobe Photoshop software and printed with a Fujix Pic-
trography digital printer (Fuji). For cytofluorography, cells were incu-
bated with mAbs for 30 min on ice, washed, and incubated with rabbit
anti–mouse Ig conjugated to fluorescein (Dako). Cells were suspended in
PBS containing ethidium homodimer (Molecular Probes), and analyzed
using a FACScalibur
 
®
 
 cytofluorograph (Becton Dickinson). Live cells
were gated based on scattering properties and low ethidium homodimer
staining.
 
Biochemical Procedures
 
Western Blotting. 
 
Confluent 143B cells grown in 6-well plates were in-
fected with rVVs and incubated for 150 min and then for 360 min in the
presence or absence of 20 
 
m
 
M cbz-LeuLeuLeucinal (zLLL). Plates were
transferred to an ice bath, and subjected to a sequential extraction to pre-
pare the nuclear matrix, according to the protocol of Staufenbiel and Dep-
pert (1984), with the exception that all buffers contained Complete
 
®
 
 pro-
tease inhibitor cocktail (EDTA-free; Boehringer Mannheim) and 10 
 
m
 
M
zLLL. Equivalent amounts of samples from each step of the procedure
were acetone precipitated, and precipitates resuspended in boiling SDS-
PAGE sample buffer (Laemmli, 1970). Samples were also prepared
from rVV-infected HeLa cells by suspending cells in ice-cold buffer con-
taining 50 mM Tris-hydrochloride (pH 8.0), 5 mM EDTA, 100 mM NaCl,
0.5% (wt/vol) CHAPS ([3-[(3-cholamidopropyl)-dimethyl-ammonio]-1-pro-
panesulfonate]),  0.2% (wt/vol) deoxycholate, and then mixed with an
equal volume of boiling SDS-PAGE sample buffer. After electrophoresis,
proteins were transferred to Immobilon
 
 
 
P membranes (Millipore) in
transfer buffer (Towbin et al., 1979) lacking SDS. Membranes were incu-
bated overnight with TBS-Casein (Bio-Rad), and then with rabbit anti-NP
antibodies, followed by peroxidase-labeled anti–rabbit IgG (Boehringer
Mannheim). Blots were developed using the ECL system (Pierce Chemi-
cal Co.), and luminescence recorded by Biomax MR film (Kodak). Images
were digitized by a flat bed scanner, assembled using Adobe Photoshop
software, and printed with a Fujix Pictrography digital printer.
 
[
 
35
 
S]Met Labeling. 
 
143 cells infected 3 h previously were incubated in
Met-free DMEM with 100 
 
m
 
M lactacystin (LC) for 40 min, and then radi-
olabeled by 5 min of incubation with [
 
35
 
S]Met. After washing, cells were
chased at 37
 
8
 
C for up to 120 min in Met containing DMEM. At appropri-
ate times, 2 
 
3
 
 10
 
6
 
 cells were removed to ice. Cells were incubated with 1%
(vol/vol) Triton X-100 (TX100) containing buffer and centrifuged at
15,000 
 
g
 
 for 10 min. Supernatants and pellets were suspended in boiling
SDS-PAGE sample buffer boiled for 5 min, and analyzed by SDS-PAGE.
Images of autoradiographs of the dried gels were digitized by a flat bed
scanner, assembled using Adobe Photoshop software and printed with a
Fujix Pictrography digital printer. The radioactivity present in dried gels
was quantitated using a PhosphorImager (Molecular Devices) and the
screens supplied by the manufacturer. The VV protein shown in Fig. 2 a
was used as an internal standard for normalization of the amount of pro-
tein recovered from each sample.
 
Results
 
Modification of NP Results in Enhanced Generation of 
Antigenic Peptides
 
The NP from the PR8 influenza virus is a 498-residue pro-
tein that is transported to the nucleus via multiple nuclear
localization sequences (Wang et al., 1997). We genetically
engineered NP to contain a 29-residue sequence nearly
identical to that from JAK1 kinase proposed to enhance
the generation of antigenic peptides by targeting the pro-
tein to proteasomes (Realini et al., 1994). In addition, we
appended to the COOH terminus a peptide corresponding
to residues 257–264 from chicken ovalbumin (OVA). This 
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peptide binds tightly to the H-2 K
 
b
 
 MHC class I molecule,
and K
 
b–
 
Ova
 
257-264
 
 complexes can be easily quantitated
cytofluorographically using a mAb (25-D1.16) specific for
this complex (Porgador et al., 1997). As a control, the
peptide was also expressed at the COOH terminus of
wild-type NP (this is termed NP
 
pep
 
 and the other construct
dNP
 
pep
 
).
 
After 6 h of infection of L-K
 
b
 
 cells with rVVs express-
ing NP
 
pep
 
 or dNP
 
pep
 
, approximately threefold more K
 
b–
 
Ova
 
257-264
 
 complexes were present on the surface of VV-
dNP
 
pep
 
–infected cells as determined cytofluorographically
after indirect immunofluorescence (Fig. 1, top histogram).
Incubation of cells with the highly specific irreversible pro-
teasome inhibitor LC resulted in the nearly complete inhi-
bition of complex expression from the chimeric proteins
and from OVA, the parent protein (Fig. 1, bottom histo-
gram). There was only a slight effect on cells infected with
a rVV expressing Ova
 
257-264
 
 as a cytosolic minigene prod-
uct (a single Met is appended to the NH
 
2
 
 terminus to en-
able efficient translation), consistent with the interpreta-
tion that LC acts by preventing proteasome liberation of
Ova
 
257-264
 
 (or a proteolytic intermediate) from NP
 
pep
 
,
dNP
 
pep
 
, and OVA, and not by interfering with VV gene
expression or delivery and loading of peptides onto K
 
b
 
molecules.
 
Metabolic Stability of dNP
 
pep
 
 and NP
 
pep
 
Increased protein degradation is associated with enhanced
generation of antigenic peptides (Tevethia et al., 1983;
Townsend et al., 1988). To investigate the more efficient
production of Ova
 
257-264
 
 from dNP
 
pep
 
, we examined the
metabolic stability of dNP
 
pep
 
 and NP
 
pep
 
 in the presence
and absence of LC. rVV-infected cells were labeled for 5
min with [
 
35
 
S]Met and chased for up to 2 h at 37
 
8
 
C. Pro-
teins present in TX100-soluble and insoluble material
were separated by SDS-PAGE and the amounts of NP
present in gel migrating with the expected mobility were
determined by PhosphorImager analysis (Fig. 2). The total
amount of NP
 
pep
 
 recovered remained nearly constant
throughout the chase period, with the solubility decreasing
Figure 1. Proteasome-dependent production of Ova257-264 from
VV-encoded proteins. L-Kb cells incubated for 90 min in the ab-
sence (top) or presence (bottom) of 50 mM LC were infected for
8 h with the indicated rVV in the presence or absence of LC, re-
spectively. Cells were stained with 25-D1.16 mAb and analyzed
by cytofluorography.
Figure 2. Proteasome-dependent degradation of
dNPpep. 143B cells were pulse radiolabeled with
[35S]Met and chased for up to 120 min at 378C in
the presence or absence of LC. Radioactive pro-
teins soluble in 1% TX100 (sol) or insoluble
(ins) were separated by SDS-PAGE and the
bands corresponding to dNPpep or NPpep located
in the dried gel (a) and quantitated (b) after nor-
malization using a VV-encoded protein as an in-
ternal standard (indicated as VV). 
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in a time-dependent manner to a plateau value. This corre-
sponds with the transport of NP
 
pep
 
 into the nucleus where
it is partially TX100 insoluble. As expected, the process
was unaffected by LC. By contrast, in the absence of LC,
recovery of both soluble and insoluble dNP
 
pep
 
 decreased
with time. Importantly, LC selectively increased the recov-
ery of insoluble dNP
 
pep
 
, without affecting soluble dNP
 
pep
 
.
We interpret this data to indicate that, first, insertion of
the JAK1 sequence into dNP
 
pep
 
 greatly enhances its degra-
dation by proteasomes, and, second, that the form di-
gested by proteasomes is insoluble in TX100. These find-
ings predict that incubation of cells with proteasome
inhibitors should result in the accumulation of dNP
 
pep
 
 in
cells.
 
Intracellular Localization of dNP
 
pep
 
This prediction was first confirmed by immunofluores-
cence of fixed and permeabilized rVV-infected cells using
rabbit antibodies raised to the NH
 
2
 
 terminus of unmodi-
fied NP (anti-NH
 
2
 
). In the absence of proteasome inhibi-
tors, staining of dNP
 
pep
 
 observed using a laser scanning
confocal microscope (LCSM) was only slightly above
background autofluorescence levels (data not shown). In
the presence of either LC (data not shown) or the revers-
ible proteasome inhibitor zLLL, dNP
 
pep
 
 was detected in
three locations: weak staining of the nuclear body (exclud-
ing the nucleoli), and strong staining of small nuclear sub-
structures (Fig. 3, first row) and, in some cells, a cytoplas-
mic structure that was often juxtanuclear (Fig. 3, third and
fourth rows, arrows). This differs markedly from the stain-
ing pattern of NP
 
pep
 
 (Fig. 3, second row), which like wild-
type NP (not shown) strongly stains the nuclear body in
the presence or absence (not shown) of proteasome inhib-
itors.
We colocalized the focal staining of dNP
 
pep
 
 with anti-
bodies specific for defined cellular structures. The nuclear
structures colocalized with those stained by a mouse mAb
(Fig. 3) or human autoimmune antibodies (see Fig. 5) spe-
cific for proteins present in PODs. PODs are enigmatic
0.3–1.0-
 
m
 
m-diameter macromolecular complexes com-
prised of 
 
.
 
20 different proteins that are attached to the
nuclear matrix (Sternsdorf et al., 1997). The cytoplasmic
structure surrounded the staining obtained with a mAb
specific for 
 
g
 
-tubulin, which identifies the pair of cen-
trioles present at the microtubule organizing center
(MTOC), the site where microtubules originate.
The accumulation of dNP
 
pep
 
 in PODs and the MTOC is
not simply the result of prolonged overexpression. If cells
were infected with rVV for 2–4 h in the absence of protea-
some inhibitors, dNP
 
pep
 
 was detected by anti-NH
 
2
 
 anti-
body staining in PODs and the MTOC as early as 30 min
after adding zLLL in a small percentage of cells (data not
shown), and by 90 min, in a high percentage of cells (see
Fig. 8). In both circumstances, this represents the rapid ac-
cumulation of newly synthesized dNP
 
pep
 
, since it did not
occur if protein synthesis inhibitors were added with
zLLL.
 
dNP
 
pep
 
 Present in PODs and MTOC Is Resistant to 
Detergent and High Salt Extraction and Present in High 
M
 
r
 
 Ubiquitinated Forms
 
PODs can be partially purified by progressive extraction
designed to isolate the nuclear matrix (Staufenbiel and
Deppert, 1984). This was performed biochemically and cy-
toimmunochemically. rVV-infected 143B cells incubated
with zLLL were subjected sequentially to NP-40, DNase I,
high salt, DNase I/RNAase, and then fixed with parafor-
maldehyde and examined using the LCSM after staining
with anti-NH
 
2
 
 and anti-POD antibodies. Under these con-
ditions dNP
 
pep
 
 was easily detected in PODs and the
MTOC (Fig. 4 C, arrow), whereas the low level staining of
remaining NP
 
pep
 
 was in a pattern not clearly related to
PODs.
Material recovered in the supernatant at each step of
the extraction procedure (and a final step with Empigen
BB to extract nuclear matrix–associated proteins, includ-
ing those in PODs) was characterized by Western blotting
using the anti-NH
 
2
 
 antibodies. Almost all of the NP
 
pep
 
 ex-
pressed in the presence (Fig. 4 A) or absence (data not
shown) of zLLL was recovered in the first three steps of the
fractionation process. The major species recovered mi-
grated with the expected mobility (arrowhead). In addition,
faster migrating species were present that were probably
generated by proteolysis during the extraction procedure.
Figure 3. dNPpep rescued by zLLL localizes in
PODs and the MTOC. rVV-infected 143B cells
were incubated for 3 h before the addition of 20
mM zLLL. After 6.5 h, cells were fixed, perme-
abilized, stained with the indicated antibodies,
and imaged with the LCSM. The second row dis-
plays cells expressing NPpep, in the first and third,
cells expressing dNPpep. In the bottom row,
dNPpep expressing cells were first extracted with
1% NP-40 and then fixed with methanol/acetone
(80:20) for 15 min at 2208C to enable staining
with the g-tubulin–specific mAb. Arrows point
to the MTOC. Gray-scale images on the sides are
merged in the middle with the color indicated by
the text describing the antibody specificity. Bar,
10 mM. 
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In the absence of zLLL, the small amounts of dNP
 
pep
 
that were present behaved similarly to NP
 
pep
 
, being recov-
ered in the first and third steps of the fractionation (Fig. 4
A). In the presence of zLLL, similar amounts of dNP
 
pep
 
were recovered in these fractions, but now a large amount
of dNP
 
pep
 
 was recovered from the final Empigen BB ex-
traction step. Notably, in addition to dNP
 
pep
 
 that migrated
with the expected mobility (arrowhead), several lower mo-
bility species were recovered at this stage, as well as the
higher mobility species that probably represent proteolytic
fragments.
The nature of the lower mobility forms of dNP
 
pep
 
 was
examined by Western blotting of whole cell lysates of
zLLL-treated HeLa cells infected with rVVs expressing
dNP
 
pep
 
, NPpep, or a control protein (OVA). Using anti-
NH2 antibodies, the ladder-like nature of the higher Mr
forms of dNPpep could be easily appreciated (Fig. 4 B). By
contrast, only a few higher Mr forms were specifically de-
tected (and at much lower levels) in NPpep-expressing cells
(compare to OVA-expressing cells). Calculation of the
Mrs of the lower mobility dNPpep bands revealed an 8.1-
kD difference, close to the expected Mr of Ub (8.5 kD), in-
dicating that dNPpep is ubiquitinated. In the same experi-
ment we used an antiserum from a rabbit immunized with
a synthetic peptide comprising the COOH terminus of NP.
This reacted strongly with unmodified dNPpep or NPpep,
but failed to detectably bind to any of the higher Mr forms
of dNPpep or NPpep. As there are no Lys residues in the
COOH-terminal NP peptide to serve as targets for ubiq-
uitination, the inability of the antibody to bind the higher
Figure 4. Fractionation and biochemical character-
ization of dNPpep. (A) Extracts from rVV-infected
143B cells incubated with or without 20 mM zLLL
were analyzed by Western blotting using anti-NH2
antibodies. Note that the panel on the left is from a
different gel than that on the right, and that the
corresponding bands are more compressed. (B)
HeLa cells infected with the rVV indicated for 90
min were incubated for an additional 3.5 h in the
presence of 40 mM zLLL. Total cell extracts were
analyzed by Western blotting using antibodies
against the NH2- or COOH-terminal peptides. Cal-
culated Mr of the lower mobility bands indicated in
red. (C) 143B cells expressing dNPpep (left) or
NPpep (right) were extracted sequentially by NP-40,
DNase I digestion, 2 M NaCl, DNase I/RNAase di-
gestion, and then paraformaldehyde fixed, stained
with anti-PML (top) or anti-NH2 antibodies, and
analyzed using the LCSM. Gray-scale images on
the top and bottom are merged in the middle with
the color indicated by the text describing the anti-
body specificity. The arrow points to the MTOC.
(D) 143B cells infected with a control virus (C),
NPpep (N), or dNPpep (D) were labeled for 5 min
with [35S]Met and chased for 40 min. Cells were ex-
tracted as above, and acetone precipitates were an-
alyzed by SDS-PAGE and the radiolabeled pro-
teins visualized using a PhosphorImager. Shown
are the regions of the gel containing the proteins of
interest along with control cellular and VV pro-
teins. The intensity of total and NP-40 lysates was
reduced fourfold before the 16–8 bit digital conver-
sion to enable visualization of individual protein
bands in all of the fractions. Arrows indicate NPpep
and dNPpep. Based on PhosphorImager quantita-
tion (and taking into account sample recovery), 2.3-
fold more NPpep is present in total lysates than
dNPpep, whereas 6.8-fold more dNPpep is recovered
in the Empigen BB step.The Journal of Cell Biology, Volume 146, 1999 118
Mr forms may be due to either cleavage of a short segment
of the COOH terminus, or to steric effects of ubiquitina-
tion on antibody access to the COOH terminus.
Based on these findings we conclude first that the bulk
of dNPpep that is normally degraded by proteasomes accu-
mulates in TX100/NP-40–insoluble forms concentrated in
PODs and the MTOC when proteasomes are inhibited,
and second, that a fraction of this material is present in
modified high Mr forms resulting at least in part from
ubiquitination. Due to uncertainties associated with effi-
ciencies of recovering and detecting antigens in Western
blots, the ratio of ubiquitinated to nonubiquitinated
dNPpep cannot be determined by this method. It is worth
noting, however, that at least some of the loss in the total
amount of [35S]Met labeled dNPpep in LC-treated cells re-
covered over the 2-h chase period (Fig. 2 b) is due to ubiq-
uitination with its attendant alteration in electrophoretic
mobility.
Transport of dNPpep to PODs/MTOC in the Absence of 
Proteasome Inhibitors
The failure to detect dNPpep in PODs/MTOC in the ab-
sence of proteasome inhibitors raises two possibilities: the
delivery of dNPpep to PODs/MTOC occurs only when pro-
teasomes are blocked; and dNPpep is delivered to PODs/
MTOC in the absence of proteasome inhibitors but is de-
graded too rapidly for cytochemical detection.
To address this issue, we labeled rVV-infected cells ex-
pressing NPpep or dNPpep with [35S]Met for 5 min, chased
for 40 min, sequentially fractionated cells as above, and
analyzed the fractions by SDS-PAGE, again taking advan-
tage of the shut down of host proteins to visualize NP and
dNPpep in an antibody-independent manner (Fig. 4 D).
Consistent with the prior results, more NPpep (z2.3-fold) is
present in total cell lysates than dNPpep, and the bulk of
NPpep is recovered in the first three fractionation steps. By
contrast, less dNPpep is recovered from the DNase and
high salt extracts, whereas its recovery in the Empigen BB
extraction step is enhanced approximately sevenfold rela-
tive to NPpep. This finding is consistent with the idea that
dNPpep is delivered to PODs in the absence of proteasome
inhibitors.
Effects of zLLL and dNPpep Expression on the 
Distribution of Cellular Constituents of the 
Degradation Machinery
We next examined the effects of zLLL and dNPpep expres-
sion on the distribution of cellular proteins in rVV-
infected cells expressing dNPpep or dNPpep with GFP
added to the COOH terminus, as well as cells transiently
transfected with plasmids encoding the GFP-fusion pro-
teins. dNPpep was detected using either antibody staining
of fixed and permeabilized cells or by GFP autofluores-
cence in fixed or live cells. Similar results were obtained
from each of these vector/detection systems, demonstrat-
ing that the findings are not limited to VV-infected cells,
and that the intracellular localization of dNPpep by anti-
bodies is not biased by fixation/permeabilization/penetra-
tion artifacts. In the interest of brevity, results will be
shown only for rVV-expressed dNPpepGFP. PODs were
detected using sera from patients with PBC which contain
Abs to PML and other POD proteins, poly Ub with a
mAb (clone FK2) nonreactive with free Ub (Fujimuro et
al., 1994), proteasomes using a mixture of two mAbs
(MCP20 and 21) reactive with native proteasome subunits
(Hendil et al., 1995), and molecular chaperones with vari-
ous monoclonal and polyclonal antibodies.
In both live and fixed dNPpepGFP-expressing cells
treated with zLLL for 4 h, fluorescent GFP was highly
concentrated in PODs and the MTOC (Fig. 5, arrows
Figure 5. Effect of dNP expression on intracellular
localization of components of the Ub-proteasome
pathway. 143B cells infected for 4 h with VV-
dNPpepGFP were incubated for an additional 4 h in
the presence of 10 mM zLLL, fixed, permeabilized
and stained for cellular components using the anti-
bodies indicated. dNPpepGFP was located by its au-
tofluorescence. Gray-scale images in each column
are merged on the bottom with the color indicated
by the text describing the antibody specificity. Ar-
rows point to the MTOC. Bar, 10 mm.Antón et al. Viral Antigen Degradation 119
point to the MTOC). The autofluorescence of dNPpepGFP
indicates that the GFP domain is properly conformed,
demonstrating that dNPpepGFP need not be completely
denatured to localize to these structures. The accumula-
tion of dNPpepGFP in these sites was accompanied by re-
cruitment of poly Ub, proteasomes, and HSC70 from their
normal diffuse distribution in the nucleus and cytoplasm,
often to the extent that staining was reduced elsewhere in
the cell (compare to Fig. 6; the distribution of protea-
somes, not shown, is similar to poly Ub). While dNPpep
and poly Ub filled the MTOC, in many cells proteasomes
and HSC70 formed a ring around MTOC. The redistribu-
tion of cellular proteins is a specific effect of inhibiting
proteasomes, as similar results were obtained with LC
(data not shown). A survey of mAbs specific for other mo-
lecular chaperones (data not shown) revealed HSP27 re-
cruited PODs similarly to HSC70 and somewhat less
strongly to the MTOC, and HSP70 was recruited weakly
to both sites. The distribution of a number of other cytoso-
lic chaperones (HSP110, HSP90, HSP60, HSP56, HSP47,
and HSP40) was not noticeably affected by dNPpep expres-
sion, and none were concentrated in either PODs or the
MTOC.
In parallel experiments we examined the effects of
zLLL on the distribution of the same cellular proteins in
uninfected cells (Fig. 6), or VV-infected cells expressing
NPpep, NPpepGFP, or GFP (data not shown). Infection with
these rVVs had no major effects on the distribution of cel-
lular proteins in untreated or zLLL-treated cells. In un-
treated uninfected cells, low levels of poly Ub were con-
centrated in a few PODs in some cells, but neither HSC70
nor proteasomes (data not shown) were concentrated in
PODs. None of these cellular proteins were concentrated
in the MTOC. After 6 h of zLLL treatment, poly Ub and
HSC70 were clearly recruited to PODs and the MTOC.
We did not detect proteasome recruitment to either the
MTOC or PODs after zLLL treatment (not shown).
These data demonstrate that exposure of cells to protea-
some inhibitors results in the accumulation of HSC70,
HSP27, and poly Ub at PODs and the MTOC. Expression
of dNPpep in the presence of proteasome inhibitors accel-
erates and enhances these effects, and also results in re-
cruitment of proteasomes to these structures.
Subcellular Localization of Altered Conformational 
States of dNPpep
The conformational status of various forms of NP in cells
was examined using other NP-specific antibodies. IC5-1B7
and HB65 are NP-specific mAbs that react with native NP
and do not react with SDS-denatured NP in Western blots
or when denatured virus is adsorbed to polyvinyl (Yewdell
et al., 1981; Yewdell, J., unpublished results). In cells ex-
pressing NP or NPpep, IC5-1B7 and HB65 colocalized
nearly perfectly with anti-NH2 antibodies, and the intensi-
ties of staining with the mAbs and the polyclonal serum
were closely parallel, indicating that NP detected by the
anti-NH2 antibodies is largely in a folded conformation by
this criterion (data not shown). The small quantities of
dNPpep present in cells not treated with proteasome inhibi-
tors stained equally with the mAbs and the anti-NH2 anti-
serum, indicating that conformed molecules are preferen-
tially spared from degradation (data not shown).
Figure 6. Effect of proteasome inhibitors on the in-
tracellular localization of components of the Ub-
proteasome pathway in uninfected cells. 143B cells
were incubated for 6 h in the presence of 21 mM
zLLL, fixed, permeabilized, and stained for cellular
components using the antibodies indicated. Gray-
scale images in each column are merged on the bot-
tom with the color indicated by the text describ-
ing the antibody specificity. Arrows point to the
MTOC. Bar, 10 mm.The Journal of Cell Biology, Volume 146, 1999 120
In dNPpep-expressing cells incubated with proteasome
inhibitors, the mAbs failed to stain PODs, while intensely
staining the MTOC (Fig. 3). This indicates that dNPpep res-
cued by proteasome inhibitors exists in multiple confor-
mations, and that most or all dNPpep in PODs is at least
partially unfolded.
In additional experiments (data not shown), we studied
the intracellular distribution of NP constructs using the
anti-COOH antiserum for immunofluorescence. When
tested against VV-NP– or VV-NPpep–infected cells, stain-
ing with this serum closely paralleled staining with HB65
or IC5-1B7 as detected by double immunofluorescence.
When used to stain dNPpep rescued by proteasome inhibi-
tors, it strongly stained both the MTOC and PODs. Since
this antiserum does not bind to ubiquitinated forms of
dNPpep (Fig. 4 B), this extends the biochemical data to
demonstrate that nonubiquitinated dNPpep is present in
PODs and the MTOC.
Extension of Findings to Other Forms of NP
We examined the behavior of two other forms of rapidly
degraded PR8 NP, one consisting of the first 168 residues
of the protein (NP1-168), the other full length NP with
amino acid substitutions at residues 148 (Y®H) and 282
(G®R) (NPDM). Both colocalized to PODs and the
MTOC in a proteasome inhibitor–dependent manner as
demonstrated using anti-NH2 Abs, and recruited the same
array of cellular proteins as dNPpep (data not shown). In
contrast to dNPpep, NPDM was detected in PODs by the
HB65 mAb, demonstrating that a more conformed form
of NP can localize to PODs.
It was even possible to induce wild-type NP to localize
to PODs and the MTOC by exposing VV-NP–infected to
cells to canavanine, an amino acid analogue of Arg that in-
duces protein misfolding (Fig. 7). NP in PODs and the
MTOC was detected by anti-COOH but not anti-NH2
Abs, possibly due to the replacement of Arg in the NH2-
terminal peptide with canavanine (the COOH peptide
used for Ab generation does not contain Arg). In addition,
large amounts of NP were now detected in the cytosol, an
effect possibly related to canavanine modification of the
nuclear localization signal. NP in PODs and MTOC re-
cruited poly Ub, proteasomes, and HSC70. Notably this
occurred in the absence of proteasome inhibitors, suggest-
ing that the degradation machinery (which could also be
affected by canavanine) was compromised under these
conditions, either as a result of having to cope with vast
quantities of proteins misfolded by incorporation of cana-
vanine, or canavanine-induced modifications in the ma-
chinery.
Together, these findings indicate that, first, that the ef-
fects with dNPpep are not due to unique features of the
protein conferred by the JAK1 sequence but are a general
feature of misfolded PR8 NP, and, second, that similar ef-
fects can occur in the absence of proteasome inhibitors.
Proteasome-dependent In Situ Degradation of dNPpep
The accumulation of dNPpep in PODs and the MTOC in
proteasome-inactivated cells suggested that these struc-
tures serve as sites for proteasome-mediated destruction
of dNPpep. To test this idea, TK2 cells were infected with
VV-dNPpep GFP for 4 h to maximize the rate of dNPpep
translation, incubated with zLLL for 90 min to accumulate
a small but detectable amount of dNPpep in a high percent-
Figure 7. Effect of canavanine on intracellular lo-
calization of NP and cellular proteins. 143B cells in-
fected for 2 h with VV-NP were incubated for an
additional 6 h in the presence of 15 mM canava-
nine. Cells were fixed, permeabilized, and stained
with the antibodies indicated. NP stained by anti-
COOH antisera is shown in the right column.
Gray-scale images on the left and right are merged
in the middle column with the color indicated by
the text describing the antibody specificity. Arrows
point to the MTOC. Bar, 10 mm.Antón et al. Viral Antigen Degradation 121
age of cells, and then for 4 h in the absence of zLLL but in
the presence of protein synthesis inhibitors to shut off ad-
ditional dNPpep synthesis (Fig. 8). After 90 min in zLLL,
dNPpep GFP was detected in PODs and the MTOC in most
cells. Over the 4-h reversal period, dNPpepGFP nearly
completely disappeared (similar results were obtained in
other experiments in which dNPpep was detected using
anti-NH2 Abs; data not shown). This process was depen-
dent on active proteasomes, since dNPpepGFP persisted in
similar quantities in PODs and the MTOC if cells were in-
cubated with zLLL and the protein synthesis inhibitors.
Based on these findings, we conclude that PODs and the
MTOC serve as sources of substrates for proteasomes, and
given the recruitment of proteasomes to these sites, are
likely to represent sites of proteasome digestion.
We next related these findings to antigen processing. Kb
was expressed in TK2 cells by coinfection with a rVV ex-
pressing Kb and mouse b2-microglobulin, and the expres-
sion of cell surface Kb–Ova257-264 complexes quantitated
cytofluorographically after indirect staining with the 25-
D1.16 mAb (Fig. 9). Levels of background staining were
controlled for by infection with VV-NP. As with L-Kb cells
(Fig. 1), Kb–Ova257-264 complexes are produced more effi-
ciently from dNPpep than NPpep; in this case the difference
is even more pronounced (six- versus threefold increase in
mean fluorescence). To correlate the disappearance of
dNPpep from PODs and the MTOC with proteasome medi-
ated generation of Ova257-264, cells were infected for 4 h in
the continuous presence of zLLL, washed, and incubated
for 4 h in the presence of protein synthesis inhibitors with-
out (EC) or with zLLL (zLLL EC). In the continued pres-
ence of zLLL (zLLL EC) no complexes were generated
from dNPpep or NPpep, since levels of staining of VV-NP–,
VV-NPpep–, and VV-dNPpep–infected cells were identical.
As described above (Fig. 1), zLLL had little effect on the
generation of complexes by cells expressing the cytosolic
minigene product, OvaM257-264. Removal of zLLL in the
presence of protein synthesis inhibitors was accompanied
by the generation of a signal in dNPpep-expressing cells
above the staining of NP-expressing cells (EC). Although
the shift in the curve is relatively small, it represents 31% of
the signal obtained in the continuous absence of inhibitors
(no inhibitor), and in absolute terms, roughly 1,000 Kb–
Ova257-264 complexes, which is more than sufficient for trig-
gering most T cells. The effectiveness of the protein synthe-
sis inhibitors is clearly demonstrated by the background
staining of cells treated with inhibitors from the initiation of
the infection (EC start), even if cells were infected with the
rVV expressing the cytosolic minigene product. In contrast
to results with dNPpep, Kb–Ova257-264 complexes were not
generated from NPpep upon removal of zLLL. These find-
ings indicate that removal of zLLL from cells allows protea-
somes to generate peptides from the dNPpep that accumu-
lates in the cells (but not from NPpep), and is consistent with
the idea the peptides (or their precursors) are generated at
PODs, the MTOC, or at both of these locations.
Figure 8. Proteasome-mediated in situ degradation of
dNPpep and generation of antigenic peptides. 143B
cells infected for 4 h with VV-dNPpepGFP were incu-
bated for an additional 90 min in the presence of 10
mM zLLL in the absence (2909 zLLL) or presence of
protein synthesis inhibitors emetine (25 mM) and cy-
cloheximide (25 mM) (2909 zLLL EC) and then
fixed, or washed, and incubated for 4 h in protein
synthesis inhibitors in the absence (2409 EC) or pres-
ence of zLLL (2409 zLLL EC) and then fixed. Cells
were permeabilized and stained using PBC antiserum.
dNPpepGFP was located by its autofluorescence. Bar,
10 mm.The Journal of Cell Biology, Volume 146, 1999 122
Discussion
We studied the fate of dNPpep as a model protein and class
I–restricted antigen with a nuclear localization sequence
that is ubiquitinated and degraded by proteasomes. Block-
ing proteasomal digestion results in the accumulation of
dNPpep in a highly insoluble form, a portion of which is
ubiquitinated. Immunofluorescence with a peptide-spe-
cific antiserum that does not detectably react with ubiquit-
inated substrate reveals that nonubiquitinated dNPpep is
present at both the MTOC and PODs. The substrate-
dependent enhanced recruitment of poly Ub to these
structures clearly indicates that Ub-conjugated dNP is also
present. This, together with the substrate-dependent re-
cruitment of HSC70, which is required for the in vitro
polyubiquitination of some proteins (Bercovich et al.,
1997), is consistent with the following model: denatured
dNPpep is chaperoned by HSC70 (and/or HSP27) to PODs
and the MTOC, where it becomes an insoluble substrate
for polyubiquitination and is degraded in situ by protea-
somes. Several lines of evidence clearly indicate that com-
plete denaturation of NP is not necessary for its delivery to
PODs and the MTOC.
The idea that polyubiquitination of misfolded NP occurs
at these sites is favored by several considerations. First,
given the low solubility of ubiquitinated dNPpep, its de-
struction at its site of ubiquitination would bypass the
need for special mechanisms to transport it to another cel-
lular site for disposal. Second, the rapid diffusion of GFP-
tagged proteasomes visualized in viable cells (Reits et al.,
1997) is fully consistent with a “search and destroy” capa-
bility for proteasomes. Third, and most directly, we have
found that prolonged treatment with proteasome inhibi-
tors (.2 h) reduces the ability of cells to polyubiquitinate
proteins (our unpublished results), presumably due to a
decrease in the free Ub pool (Mimnaugh et al., 1997). Lim-
iting levels of free Ub would account, first, for the failure
of cells to completely ubiquitinate dNPpep at PODs and the
MTOC, and, second, for the plateau observed in the level
of unmodified dNPpep recovered from LC-treated cells af-
ter pulse radiolabeling (Fig. 2 b).
We believe that a subset of cellular proteins behaves
similarly to dNPpep, since polyubiquitin and HSC70 are re-
cruited to PODs and the MTOC of uninfected cells
treated with proteasome inhibitors. Clearly, however, the
effect is much less dramatic. This is not surprising given
that in VV-infected cells infected for 2 h onwards, dNPpep
represents z5–10% of all newly synthesized protein, and
that most of it denatures rapidly after synthesis. This quan-
titative difference probably accounts for the failure of pro-
teasome inhibitors to recruit proteasomes to PODs and
the MTOC in cells not expressing dNPpep.
There is a considerable body of work relevant to these
findings. Wojcik et al. (1996) reported that treating cells
with proteasome inhibitors results in the accumulation of
proteins (including proteasomes and Ub) at the MTOC:
sufficient in fact to enable preferential staining of the
MTOC in fixed cells with the protein stain amido black.
Terming these structures “proteolysis centers,” they pro-
posed that normal degradation of proteins occurs in this
location. These findings were extended recently by John-
ston et al. (1998), who demonstrated the presence of ubiq-
uitinated proteasome substrates (misfolded forms of inte-
gral membrane proteins exported from the ER) at the
same location (termed “aggresomes” by these authors) in
the absence of proteasome inhibitors.
We extend these findings by demonstrating that: pro-
teins with a nuclear localization sequence can also be de-
graded in proteolysis centers/aggresomes; proteins des-
tined for destruction in the MTOC can retain at least
portions of their native structure as indicated by binding to
conformation-specific antibodies, or in the case of GFP fu-
sion proteins, maintenance of autofluorescence; specific
molecular chaperones are involved in the process; poly-
ubiquitin may be added to substrates at this site; and sub-
strates present in the MTOC are degraded by protea-
somes.
The last four points apply also to PODs, providing the
first conclusive evidence that these structures serve as a
site for proteasomal degradation of ubiquitinated proteins,
which as we argue above, is probably secondary to its serv-
ing as a site ubiquitination of denatured proteins. PODs
have been implicated in a number of cellular processes, in-
cluding tumorigenicity, apoptosis, and viral replication
(Sternsdorf et al., 1997). Herpesviruses, adenoviruses, and
papilloma viruses all encode proteins that localize to
PODs, in some cases, disrupting the PODs. In addition to
PML (the “P” in PODs), other examples of the 201 known
inhabitants of PODs include Sp100, HAUSP, and SUMO-1
Figure 9. Antigenic peptides are generated from a
pool of dNPpep accumulated in the presence of pro-
teasome inhibitor. 143B cells were coinfected with
a rVV expressing Kb and mouse b2m and a rVV ex-
pressing the protein indicated. Cells were infected
for 4 h in the presence of 10 mM zLLL to prevent
the generation of Kb–Ova257-264 complexes, washed,
and incubated for 4 h in protein synthesis inhibitors
in the presence (bottom left histogram) or absence
(bottom right histogram) of zLLL. As controls,
cells were incubated for 8 h in the absence of inhib-
itors (top left histogram) or in the presence of pro-
tein synthesis inhibitors (top right histogram). Cells
were indirectly stained with the 25-D1.16 mAb to
quantitate the number of cell surface Kb-Ova257-264
complexes.Antón et al. Viral Antigen Degradation 123
(also known as PIC1). Significantly, both SUMO-1 and
particularly HAUSP are related to the Ub-proteasome
pathway. SUMO-1 is a Ub homologue that covalently
modifies both PML and Sp100. Unlike Ub however,
SUMO-1 modification appears to mainly affect the local-
ization of its substrates and not their degradation, as both
PML and Sp100 are localized to PODs only in their modi-
fied forms which are metabolically stable (as are other
SUMO-1–modified proteins) (Saitoh et al., 1997). When
used as an alternative for Ub, SUMO-1 is even known to
prevent proteasomal degradation of proteins (Desterro et
al., 1998). HAUSP is a Ub-dependent hydrolase, that re-
moves Ub, but not SUMO-1 from substrates (Everett et
al., 1998), and its presence in PODs is consistent with the
idea that PODs serve as a center for protein ubiquitination
and deubiquitination.
A chromosomal translocation characteristic for acute
PML (APL) results in the creation of a fusion protein
comprised of PML and the retinoic acid receptor a
(RARa). The PML-RARa fusion protein acts as a domi-
nant negative mutant, disrupting the integrity of PODs.
Exposure of APL cells to retinoic acid returns the cells to
a nontransformed phenotype concomitantly with the ref-
ormation of PODs and the degradation of the fusion pro-
tein (Daniel et al., 1993; Dyck et al., 1994; Weis et al.,
1994). Alternatively, As2O3 treatment of normal or APL
cells results in the recruitment of both PML and PML-
RARa to PODs as well as their degradation (Zhu et al.,
1997). The retinoic acid–induced degradation of PML-
RARa is blocked by LC, implicating proteasomes in the
process (Yoshida et al., 1996). Our findings are consistent
with the idea that these proteins are degraded in PODs.
Everett et al. (1998) have shown that herpes simplex vi-
rus–induced destruction of PODs is mediated by the viral
protein Vmw110 and is blocked by proteasome inhibitors.
Vmw110 induces the proteasome-mediated destruction of
PML and nuclear protein kinase. Vmw110 binds to
HAUSP, but this is not required for its localization to
PODs, or POD disruption of destruction of the kinase
(Parkinson et al., 1999). These findings again support our
conclusion that PODs serve as a general site of protea-
some degradation, but Vmw110 probably induces protea-
some degradation in multiple cellular sites, since Vmw110
mutants that do not localize to PODs can induce kinase
degradation (Everett et al., 1999).
The involvement of PODs in the degradation of mis-
folded proteins also helps explain findings regarding mu-
tant alleles of ataxin 1 that encode multiple copies of a
polyglutamine domain present in the normal protein.
These alleles are associated with a variety of inherited dis-
eases of the nervous system. Ataxin 1 is normally present
in small nuclear dots distinct from PODs. Mutant forms of
ataxin 1 expressed in the absence of proteasome inhibitors
are present in POD-like structures that contain PML and
recruit Ub, proteasomes, HSP70, and HSP40 (Skinner et
al., 1997; Cummings et al., 1998). It is uncertain to what ex-
tent ataxin versus other polyglutamine-containing proteins
recruited into ataxin-initiated structures accounts for the
recruitment of Ub, proteasomes, and chaperones (Perez
et al., 1998). Our findings suggest that one (or more) of
these misfolded proteins is recruited to PODs in associa-
tion with HSP40 and HSP70, where it is polyubiquitinated
but for some reason cannot be degraded by proteasomes,
similar to what we describe for NP synthesized in the pres-
ence of canavanine.
Finally, we have linked the destruction of dNPpep in
PODs and the MTOC to the generation of an antigenic
peptide present in the protein. Given that all protein syn-
thesis occurs in the cytosol, and that nuclear and ER pro-
teins are commonly transported to the cytosol for degra-
dation (Ciechanover, 1998), the MTOC is probably a more
general site of proteasome-mediated peptide generation,
whereas peptide generation at PODs is expected to be lim-
ited largely to the subset of proteins located in the nucleus.
It should be noted that the inner portion of the nuclear
membrane forms part of the ER, and that peptides gener-
ated in the nucleus would not necessarily need to be deliv-
ered to the cytosol to access TAP (the MHC-encoded
transporter that delivers class I ligands to the ER).
Due to the low efficiency of antigen processing, we can-
not be certain that peptides are generated from dNPpep ac-
cumulated at PODs/MTOC and not from lesser amounts
of antigen present elsewhere in the cell. Given the func-
tion of the MTOC as proteolytic centers/aggresomes, how-
ever, it would be surprising if this were not a common site
of peptide generation. Regarding PODs, there are several
published findings that would support a role in antigen pro-
cessing, perhaps even a specialized role in regulating the
process. First, the expression of PML and other POD con-
stituent proteins is enhanced by exposure of cells to inter-
ferons, which increase the expression of genes encoding
class I molecules and the other dedicated components of
the class I–processing pathway (Sternsdorf et al., 1997).
Second, PML itself has been directly implicated in the reg-
ulation of antigen processing, as modifications in PML that
disrupt PODs result in decreased transcription of antigen-
processing genes (Zheng et al., 1998). Together with our
findings, these observations suggest the following hypothe-
sis: a signal emanating from ubiquitination/proteolysis oc-
curring at PODs is involved in a positive feedback loop
that regulates antigen processing gene transcription.
We are grateful to Drs. Bloch, Hendil, and Liang for their generous gifts
of antibodies. Bethany Buschling provided outstanding technical assis-
tance.
Submitted: 3 February 1999
Revised: 26 April 1999
Accepted: 4 June 1999
References
Antón, L.C., H.L. Snyder, J.R. Bennink, A. Vinitsky, M. Orlowski, A. Porga-
dor, and J.W. Yewdell. 1998. Dissociation of proteasomal degradation of
biosynthesized viral proteins from generation of MHC class I-associated an-
tigenic peptides. J. Immunol. 160:4859–4868.
Bercovich, B., I. Stancovski, A. Mayer, N. Blumenfeld, A. Laszlo, A.L.
Schwartz, and A. Ciechanover. 1997. Ubiquitin-dependent degradation of
certain protein substrates in vitro requires the molecular chaperone Hsc70.
J. Biol. Chem. 272:9002–9010.
Bogyo, M., M. Gaczynska, and H.L. Ploegh. 1997. Proteasome inhibitors and
antigen presentation. Biopolymers. 43:269–280.
Chakrabarti, S., K. Brechling, and B. Moss. 1985. Vaccinia virus expression vec-
tor: coexpression of b-galactosidase provides visual screening of recombi-
nant virus plaques. Mol. Cell. Biol. 5:3403–3409.
Ciechanover, A. 1998. The ubiquitin-proteasome pathway: on protein death
and cell life. EMBO (Eur. Mol. Biol. Organ.) J. 17:7151–7160.
Cummings, C.J., M.A. Mancini, B. Antalffy, D.B. DeFranco, H.T. Orr, and
H.Y. Zoghbi. 1998. Chaperone suppression of aggregation and altered sub-
cellular proteasome localization imply protein misfolding in SCA1. Nat.
Genet. 19:148–154.The Journal of Cell Biology, Volume 146, 1999 124
Daniel, M.T., M. Koken, O. Romagne, S. Barbey, A. Bazarbachi, M. Stadler,
M.C. Guillemin, L. Degos, C. Chomienne, and H. de The. 1993. PML pro-
tein expression in hematopoietic and acute promyelocytic leukemia cells.
Blood. 82:1858–1867.
Desterro, J.M., M.S. Rodriguez, and R.T. Hay. 1998. SUMO-1 modification of
IkappaBalpha inhibits NF-kappaB activation. Mol. Cell. 2:233–239.
Dyck, J.A., G.G. Maul, W.H.J. Miller, J.D. Chen, A. Kakizuka, and R.M.
Evans. 1994. A novel macromolecular structure is a target of the promyelo-
cyte-retinoic acid receptor oncoprotein. Cell. 76:333–343.
Everett, R.D., P. Freemont, H. Saitoh, M. Dasso, A. Orr, M. Kathoria, and J.
Parkinson. 1998. The disruption of ND10 during herpes simplex virus infec-
tion correlates with the Vmw110- and proteasome-dependent loss of several
PML isoforms. J. Virol. 72:6581–6591.
Everett, R.D., M. Meredith, and A. Orr. 1999. The ability of herpes simplex vi-
rus type 1 immediate-early protein Vmw110 to bind to a ubiquitin-specific
protease contributes to its roles in the activation of gene expression and
stimulation of virus replication. J. Virol. 73:417–426.
Fujimuro, M., H. Sadada, and H. Yokosawa. 1994. Production and character-
ization of monoclonal antibodies specific to multi-ubiquitin chains of poly-
ubiquitinated proteins. FEBS Lett. 349:173–180.
Hendil, K.B., P. Kristensen, and W. Uerkvitz. 1995. Human proteasome analy-
sed with monoclonal antibodies. Biochem. J. 305:245–252.
Johnston, J.A., C.L. Ward, and R.R. Kopito. 1998. Aggresomes: a cellular re-
sponse to misfolded proteins. J. Cell Biol. 143:1883–1898.
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the
head of bacteriophage T4. Nature. 227:680–685.
Lee, D.H., and A.L. Goldberg. 1998. Proteasome inhibitors: valuable new tools
for cell biologists. Trends Cell Biol. 8:397–403.
Mimnaugh, E.G., H.Y. Chen, J.R. Davie, J.E. Celis, and L. Neckers. 1997.
Rapid deubiquitination of nucleosomal histones in human tumor cells
caused by proteasome inhibitors and stress response inducers: effects on
replication, transcription, translation, and the cellular stress response. Bio-
chemistry. 36:14418–14429.
Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I–restricted anti-
gen processing. Annu. Rev. Immunol. 16:323–358.
Parkinson, J., S.P. Lees-Miller, and R.D. Everett. 1999. Herpes simplex virus
type 1 immediate-early protein Vmw110 induces the proteasome-dependent
degradation of the catalytic subunit of DNA-dependent protein kinase. J.
Virol. 73:650–657.
Perez, M.K., H.L. Paulson, S.J. Pendse, S.J. Saionz, N.M. Bonini, and R.N. Pitt-
man. 1998. Recruitment and the role of nuclear localization in poly-
glutamine-mediated aggregation. J. Cell Biol. 143:1457–1470.
Porgador, A., J.W. Yewdell, Y. Deng, J.R. Bennink, and R.N. Germain. 1997.
Localization, quantitation, and in situ detection of specific peptide-MHC
class I complexes using a monoclonal antibody. Immunity. 6:715–726.
Realini, C., S.W. Rogers, and M. Rechsteiner. 1994. Proposed roles in protein-
protein association and presentation of peptides by MHC class I receptors.
FEBS Lett. 348:109–113.
Reits, E.A.J., A.M. Benham, B. Plougastel, J. Neefjes, and J. Trowsdale. 1997.
Dynamics of proteasome distribution in living cells. EMBO (Eur. Mol. Biol.
Organ.) J. 16:6087–6094.
Saitoh, H., R.T. Pu, and M. Dasso. 1997. SUMO-1: wrestling with a new ubiq-
uitin-related modifier. Trends Biochem. Sci. 22:374–376.
Skinner, P.J., B.T. Koshy, C.J. Cummings, I.A. Klement, K. Helin, A. Servadio,
H.Y. Zoghbi, and H.T. Orr. 1997. Ataxin-1 with an expanded glutamine
tract alters nuclear matrix-associated structures. Nature. 389:971–974.
Staufenbiel, M., and W. Deppert. 1984. Preparation of nuclear matrices from
cultured cells: subfractionation of nuclei in situ. J. Cell Biol. 98:1886–1894.
Sternsdorf, T., T. Grotzinger, K. Jensen, and H. Will. 1997. Nuclear dots: actors
on many stages. Immunobiology. 198:307–331.
Tevethia, S., M. Tevethia, A. Lewis, V. Reddy, and S. Weissman. 1983. Biology
of simian virus 40 (SV40) transplantation antigen (TrAg). IX. Analysis of
TrAg in mouse cells synthesizing truncated SV40 large T antigen. Virology.
128:319–330.
Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of pro-
teins from polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proc. Natl. Acad. Sci. USA. 76:4350–4354.
Townsend, A., J. Bastin, K. Gould, G. Brownlee, M. Andrew, B. Coupar,
D. Boyle, S. Chan, and G. Smith. 1988. Defective presentation to class
I–restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome
by enhanced degradation of antigen. J. Exp. Med. 168:1211–1224.
Wang, P., P. Palese, and R.E. O’Neill. 1997. The NPI-1/NPI-3 (karyopherin a)
binding site on the influenza A virus nucleoprotein NP is a nonconventional
nuclear localization signal. J. Virol. 71:1850–1856.
Weis, K., S. Rambaud, C. Lavau, J. Jansen, T. Carvalho, M. Carmo-Fonseca, A.
Lamond, and A. Dejean. 1994. Retinoic acid regulates aberrant nuclear lo-
calization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell.
76:345–356.
Wojcik, C., D. Schroeter, S. Wilk, J. Lamprecht, and N. Paweletz. 1996. Ubiq-
uitin-mediated proteolysis centers in HeLa cells: indication from studies of
an inhibitor of the chymotrypsin-like activity of the proteasome. Eur. J. Cell
Biol. 71:311–318.
Yewdell, J.W., E. Frank, and W. Gerhard. 1981. Expression of influenza A vi-
rus internal antigens on the surface of infected P815 cells. J. Immunol. 126:
1814–1819.
York, I., and K.L. Rock. 1996. Antigen processing and presentation by the class
I major histocompatibility complex. Annu. Rev. Immunol. 14:369–396.
Yoshida, H., K. Kitamura, K. Tanaka, S. Omura, T. Miyazaki, T. Hachiya, R.
Ohno, and T. Naoe. 1996. Accelerated degradation of PML-retinoic acid re-
ceptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute
promyelocytic leukemia: possible role of the proteasome pathway. Cancer
Res. 56:2945–2948.
Zheng, P., Y. Guo, Q. Niu, D.E. Levy, J.A. Dyck, S. Lu, L.A. Sheiman, and Y.
Liu. 1998. Proto-oncogene PML controls genes devoted to MHC class I anti-
gen presentation. Nature. 396:373–376.
Zhu, J., M.H. Koken, F. Quignon, M.K. Chelbi-Alix, L. Degos, Z.Y. Wang, Z.
Chen, and H. de The. 1997. Arsenic-induced PML targeting onto nuclear
bodies: implications for the treatment of acute promyelocytic leukemia.
Proc. Natl. Acad. Sci. USA. 94:3978–3983.